• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

加拿大对美国病理学家学会、国际肺癌研究协会和分子病理学协会关于 EGFR 和 ALK 检测在肺癌临床实践指南的影响。

Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada.

出版信息

Curr Oncol. 2013 Aug;20(4):220-6. doi: 10.3747/co.20.1568.

DOI:10.3747/co.20.1568
PMID:23904763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3728053/
Abstract

This paper summarizes the practical impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology lung cancer biomarkers guidelines on the lung cancer approach in Canada, providing possible practical solutions for other similar health care systems in which scientific reality needs to be constantly balanced against economic reality.

摘要

本文总结了美国病理学家学院、国际肺癌研究协会和分子病理学协会肺癌生物标志物指南对加拿大肺癌方法的实际影响，为其他类似的卫生保健系统提供了可能的实际解决方案，在这些系统中，科学现实需要不断与经济现实相平衡。

相似文献

1
Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada.加拿大对美国病理学家学会、国际肺癌研究协会和分子病理学协会关于 EGFR 和 ALK 检测在肺癌临床实践指南的影响。
Curr Oncol. 2013 Aug;20(4):220-6. doi: 10.3747/co.20.1568.
2
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.用于选择肺癌患者接受表皮生长因子受体和间变性淋巴瘤激酶酪氨酸激酶抑制剂治疗的分子检测：美国临床肿瘤学会认可美国病理学家学会/国际肺癌研究协会/分子病理学协会指南
J Clin Oncol. 2014 Nov 10;32(32):3673-9. doi: 10.1200/JCO.2014.57.3055. Epub 2014 Oct 13.
3
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.分子检测指南：选择肺癌患者接受靶向酪氨酸激酶抑制剂治疗：美国临床肿瘤学会对美国病理学家学院/国际肺癌研究协会/分子病理学会临床实践指南更新的认可。
J Clin Oncol. 2018 Mar 20;36(9):911-919. doi: 10.1200/JCO.2017.76.7293. Epub 2018 Feb 5.
4
Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.肺癌的分子检测：在 CAP/IASLC/AMP 分子检测指南发布之前，细针穿刺标本的充分性和检测优先级。
Cancer Cytopathol. 2014 Jun;122(6):454-8. doi: 10.1002/cncy.21426. Epub 2014 Apr 10.
5
National Working Group Meeting on ALK diagnostics in lung cancer.肺癌ALK诊断全国工作组会议
Asia Pac J Clin Oncol. 2014 Apr;10 Suppl 2:11-7. doi: 10.1111/ajco.12190.
6
The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer.国际肺癌研究协会肺癌分子检测全球调查。
J Thorac Oncol. 2020 Sep;15(9):1434-1448. doi: 10.1016/j.jtho.2020.05.002. Epub 2020 May 20.
7
Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.常规临床实践中非小细胞肺癌分子检测周转时间证实了CAP/IASLC/AMP指南建议的可行性：一项单中心分析
Clin Lung Cancer. 2017 Sep;18(5):e349-e356. doi: 10.1016/j.cllc.2017.03.001. Epub 2017 Mar 14.
8
Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice?将非小细胞肺癌的细胞学样本外包给转诊实验室进行表皮生长因子受体（EGFR）检测：理论与实践相符吗？
Cytopathology. 2015 Oct;26(5):312-7. doi: 10.1111/cyt.12221. Epub 2014 Nov 7.
9
Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.根据国际肺癌研究协会（IASLC）/美国胸科学会（ATS）/欧洲呼吸学会（ERS）的新型分类，肺腺癌组织学亚型、表皮生长因子受体（EGFR）/ Kirsten 大鼠肉瘤病毒癌基因（KRAS）突变状态与间变性淋巴瘤激酶（ALK）重排之间的关联。
Oncol Lett. 2016 Apr;11(4):2552-2558. doi: 10.3892/ol.2016.4233. Epub 2016 Feb 17.
10
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.用于结直肠癌评估的分子标志物：美国临床病理学会、美国病理学家学院、分子病理学会和美国临床肿瘤学会的指南。
J Clin Oncol. 2017 May 1;35(13):1453-1486. doi: 10.1200/JCO.2016.71.9807. Epub 2017 Feb 6.

引用本文的文献

1
Validity of Natural Language Processing for Ascertainment of and Test Results in SEER Cases of Stage IV Non-Small-Cell Lung Cancer.自然语言处理在监测美国国立癌症研究所监测、流行病学和最终结果（SEER）项目中IV期非小细胞肺癌病例的[具体内容缺失]和检测结果方面的有效性。
JCO Clin Cancer Inform. 2019 May;3:1-15. doi: 10.1200/CCI.18.00098.
2
Canadian perspectives: update on inhibition of -positive tumours in advanced non-small-cell lung cancer.加拿大视角：晚期非小细胞肺癌中阳性肿瘤抑制的最新进展。
Curr Oncol. 2018 Oct;25(5):317-328. doi: 10.3747/co.25.4379. Epub 2018 Oct 31.
3
Standardizing biomarker testing for Canadian patients with advanced lung cancer.为加拿大晚期肺癌患者规范生物标志物检测
Curr Oncol. 2018 Feb;25(1):73-82. doi: 10.3747/co.25.3867. Epub 2018 Feb 28.
4
Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario.改善安大略省非小细胞肺癌的分子检测和个性化医疗。
Curr Oncol. 2017 Apr;24(2):103-110. doi: 10.3747/co.24.3495. Epub 2017 Apr 27.
5
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.加拿大共识：晚期非小细胞肺癌中ALK阳性肿瘤的抑制
Curr Oncol. 2016 Jun;23(3):196-200. doi: 10.3747/co.23.3120. Epub 2016 Jun 9.
6
Ready or not? Lung cancer diagnosis in 2015.准备好了吗？2015年的肺癌诊断
Curr Oncol. 2015 Aug;22(4):239-42. doi: 10.3747/co.22.2647.

本文引用的文献

1
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.美国病理学家学会、国际肺癌研究协会和分子病理学会肺癌患者表皮生长因子受体和间变性淋巴瘤激酶酪氨酸激酶抑制剂选择的分子检测指南
Arch Pathol Lab Med. 2013 Jun;137(6):828-60. doi: 10.5858/arpa.2012-0720-OA. Epub 2013 Apr 3.
2
Effect of large tumor size on cancer-specific mortality in node-negative breast cancer.大肿瘤大小对淋巴结阴性乳腺癌患者癌症特异性死亡率的影响。
Mayo Clin Proc. 2012 Dec;87(12):1171-80. doi: 10.1016/j.mayocp.2012.07.023.
3
Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.免疫组织化学是一种可靠的筛选工具，可用于鉴定非小细胞肺癌中的 ALK 重排，并且依赖于抗体。
J Thorac Oncol. 2013 Jan;8(1):45-51. doi: 10.1097/JTO.0b013e318274a83e.
4
EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer.表皮生长因子受体酪氨酸激酶突变检测在非小细胞肺癌治疗中的应用。
Curr Oncol. 2012 Apr;19(2):e67-74. doi: 10.3747/co.19.862.
5
The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.肺癌患者靶向药物敏感性标志物筛查的成本效益分析。
Br J Cancer. 2012 Mar 13;106(6):1100-6. doi: 10.1038/bjc.2012.60. Epub 2012 Feb 28.
6
Aged vervet monkeys developing transthyretin amyloidosis with the human disease-causing Ile122 allele: a valid pathological model of the human disease.携带人类致病 Ile122 等位基因的老年恒河猴发生转甲状腺素蛋白淀粉样变性：人类疾病的有效病理模型。
Lab Invest. 2012 Mar;92(3):474-84. doi: 10.1038/labinvest.2011.195. Epub 2011 Dec 19.
7
Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.在常规实践中，对肺腺癌中 ALK 基因重排进行双重免疫组化和 FISH 检测：一项法国研究。
J Thorac Oncol. 2012 Feb;7(2):348-54. doi: 10.1097/JTO.0b013e3182381535.
8
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.系统评价和加拿大共识建议：生物标志物在非小细胞肺癌治疗中的应用。
J Thorac Oncol. 2011 Aug;6(8):1379-91. doi: 10.1097/JTO.0b013e318220cb8e.
9
Molecular diagnostics of lung carcinomas.肺腺癌的分子诊断。
Arch Pathol Lab Med. 2011 May;135(5):622-9. doi: 10.5858/2010-0625-RAIR.1.
10
Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing.小活检和细胞学肺癌的病理诊断和分类：用于分子检测的组织的策略性管理。
Semin Respir Crit Care Med. 2011 Feb;32(1):22-31. doi: 10.1055/s-0031-1272866. Epub 2011 Apr 15.